BR9808147A - Clone de ácido nucleico do vìrus da hepatite c (hcv) geneticamente engenheirado, clone plasmìdeo que abriga uma cdna do hcv de tamanho natural, dna ou rna do hcv transcrito do cdna do hcv de comprimento natural, linhagem de célula hospedeira transfectada e in vitro infectada com o hcv, animal não humano infectado com o hcv, partìcula viral do hcv, sistema de teste in vitro, isento de célula para o hcv, vacina do hcv e conjunto de teste para o hcv e processos para identificar uma linhagem de célula que é permissiva e um animal que é permissivo para a infecção por hcv, para selecionar hcv com mutações adaptativas que permitem nìveis mais altos de replicação do hcv em uma linhagem de célula permissiva, para infectar uma animal com o hcv, para propagar o hcv in vitro, para transduzir um animal suscetìvel à infecção por hcv com um gene heterólogo, para produzir partìculas virais do hcv, proteìnas de partìcula do hcv e anticorpos do hcv, para separar agentes capazes de modular a replicação do hcv, para preparar um ácido nucleico do hcv e para detectar anticorpos do hcv em uma amostra biológica de um paciente. - Google Patents

Clone de ácido nucleico do vìrus da hepatite c (hcv) geneticamente engenheirado, clone plasmìdeo que abriga uma cdna do hcv de tamanho natural, dna ou rna do hcv transcrito do cdna do hcv de comprimento natural, linhagem de célula hospedeira transfectada e in vitro infectada com o hcv, animal não humano infectado com o hcv, partìcula viral do hcv, sistema de teste in vitro, isento de célula para o hcv, vacina do hcv e conjunto de teste para o hcv e processos para identificar uma linhagem de célula que é permissiva e um animal que é permissivo para a infecção por hcv, para selecionar hcv com mutações adaptativas que permitem nìveis mais altos de replicação do hcv em uma linhagem de célula permissiva, para infectar uma animal com o hcv, para propagar o hcv in vitro, para transduzir um animal suscetìvel à infecção por hcv com um gene heterólogo, para produzir partìculas virais do hcv, proteìnas de partìcula do hcv e anticorpos do hcv, para separar agentes capazes de modular a replicação do hcv, para preparar um ácido nucleico do hcv e para detectar anticorpos do hcv em uma amostra biológica de um paciente.

Info

Publication number
BR9808147A
BR9808147A BR9808147-0A BR9808147A BR9808147A BR 9808147 A BR9808147 A BR 9808147A BR 9808147 A BR9808147 A BR 9808147A BR 9808147 A BR9808147 A BR 9808147A
Authority
BR
Brazil
Prior art keywords
hcv
animal
permissive
cell line
vitro
Prior art date
Application number
BR9808147-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Charles M Rice Iii
Alexander A Kolykhalov
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of BR9808147A publication Critical patent/BR9808147A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9808147-0A 1997-03-04 1998-02-26 Clone de ácido nucleico do vìrus da hepatite c (hcv) geneticamente engenheirado, clone plasmìdeo que abriga uma cdna do hcv de tamanho natural, dna ou rna do hcv transcrito do cdna do hcv de comprimento natural, linhagem de célula hospedeira transfectada e in vitro infectada com o hcv, animal não humano infectado com o hcv, partìcula viral do hcv, sistema de teste in vitro, isento de célula para o hcv, vacina do hcv e conjunto de teste para o hcv e processos para identificar uma linhagem de célula que é permissiva e um animal que é permissivo para a infecção por hcv, para selecionar hcv com mutações adaptativas que permitem nìveis mais altos de replicação do hcv em uma linhagem de célula permissiva, para infectar uma animal com o hcv, para propagar o hcv in vitro, para transduzir um animal suscetìvel à infecção por hcv com um gene heterólogo, para produzir partìculas virais do hcv, proteìnas de partìcula do hcv e anticorpos do hcv, para separar agentes capazes de modular a replicação do hcv, para preparar um ácido nucleico do hcv e para detectar anticorpos do hcv em uma amostra biológica de um paciente. BR9808147A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/811,566 US6127116A (en) 1995-08-29 1997-03-04 Functional DNA clone for hepatitis C virus (HCV) and uses thereof
PCT/US1998/004428 WO1998039031A1 (en) 1997-03-04 1998-02-26 Functional dna clone for hepatitis c virus (hcv) and uses thereof

Publications (1)

Publication Number Publication Date
BR9808147A true BR9808147A (pt) 2000-03-28

Family

ID=25206905

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808147-0A BR9808147A (pt) 1997-03-04 1998-02-26 Clone de ácido nucleico do vìrus da hepatite c (hcv) geneticamente engenheirado, clone plasmìdeo que abriga uma cdna do hcv de tamanho natural, dna ou rna do hcv transcrito do cdna do hcv de comprimento natural, linhagem de célula hospedeira transfectada e in vitro infectada com o hcv, animal não humano infectado com o hcv, partìcula viral do hcv, sistema de teste in vitro, isento de célula para o hcv, vacina do hcv e conjunto de teste para o hcv e processos para identificar uma linhagem de célula que é permissiva e um animal que é permissivo para a infecção por hcv, para selecionar hcv com mutações adaptativas que permitem nìveis mais altos de replicação do hcv em uma linhagem de célula permissiva, para infectar uma animal com o hcv, para propagar o hcv in vitro, para transduzir um animal suscetìvel à infecção por hcv com um gene heterólogo, para produzir partìculas virais do hcv, proteìnas de partìcula do hcv e anticorpos do hcv, para separar agentes capazes de modular a replicação do hcv, para preparar um ácido nucleico do hcv e para detectar anticorpos do hcv em uma amostra biológica de um paciente.

Country Status (9)

Country Link
US (4) US6127116A (https=)
EP (1) EP1005366A4 (https=)
JP (2) JP4094679B2 (https=)
AU (1) AU742175B2 (https=)
BR (1) BR9808147A (https=)
CA (1) CA2283464C (https=)
IL (2) IL131688A0 (https=)
WO (1) WO1998039031A1 (https=)
ZA (1) ZA981838B (https=)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235394B1 (en) 1995-08-29 2007-06-26 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US6242187B1 (en) * 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof
US20020034732A1 (en) * 1997-07-30 2002-03-21 Daniel J. Capon Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US20030028011A1 (en) * 1997-07-30 2003-02-06 Parkin Neil T. Compositions and methods for determining susceptibility of hepatitis C virus to anti-viral drugs
US6893866B1 (en) * 1997-11-28 2005-05-17 The Crown In The Right Of The Queensland Department Of Health Flavivirus expression and delivery system
DE19915178A1 (de) * 1999-04-03 2000-10-05 Univ Mainz Johannes Gutenberg Hepatitis C Virus Zellkultursystem
EP1377554A1 (en) 1999-06-16 2004-01-07 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
CA2388337C (en) * 1999-10-22 2013-01-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
DE19953854C2 (de) * 1999-11-09 2002-01-17 Max Planck Gesellschaft Verfahren zur Herstellung von Biopolymeren mit veränderten Eigenschaften
EP1233976A4 (en) * 1999-11-17 2003-06-11 Jiuping Ji SIMULTANEOUS DETECTION OF HBV, HCV AND HIV IN PLASMA SAMPLES WITH THE AID OF A MULTIPLEX FIXING TEST
US6921634B2 (en) * 1999-12-23 2005-07-26 Board Of Regents, The University Of Texas System Replication competent hepatitus C virus and methods of use
US20010055756A1 (en) * 2000-04-21 2001-12-27 Charles Pellerin Internal de novo initiation sites of the HCV NS5B polymerase and use thereof
DK1282702T3 (da) * 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
US6447994B1 (en) 2000-06-20 2002-09-10 The General Hospital Corporation Production of replicative hepatitis C virus
JPWO2002028174A1 (ja) * 2000-10-03 2004-02-12 財団法人 東京都医学研究機構 Ｃ型肝炎ウイルス感染方法
WO2002038793A2 (en) * 2000-11-07 2002-05-16 Anadys Pharmaceuticals, Inc. Hepatitis c virus constructs characterized by high efficiency replication
US20040005549A1 (en) * 2000-11-07 2004-01-08 Anadys Pharmaceuticals, Inc. Hepatitis C virus constructs characterized by high efficiency replication
MXPA03005638A (es) 2000-12-22 2004-04-05 Boehringer Ingelheim Ca Ltd Auto replicacion de la molecula de arn de virus de la hepatitis c.
MXPA03008882A (es) * 2001-03-27 2003-12-08 Vertex Pharma Composiciones y metodos utiles para la infeccion por hcv.
FR2824072B1 (fr) * 2001-04-27 2004-03-12 Centre Nat Rech Scient Procede de replication et de production du virus de l'hepatite c
WO2002090572A2 (en) * 2001-05-09 2002-11-14 Third Wave Technologies, Inc. Nucleic acid detection in pooled samples
WO2002089840A1 (en) * 2001-05-10 2002-11-14 The Regents Of The University Of California Recombinant bicistronic flaviviruses and methods of use thereof
US20040209831A1 (en) * 2002-02-20 2004-10-21 Mcswiggen James RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
US20050209180A1 (en) * 2001-05-18 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US20060211642A1 (en) * 2001-05-18 2006-09-21 Sirna Therapeutics, Inc. RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
WO2003040356A1 (en) * 2001-08-06 2003-05-15 Yangling Daiying Biological Engineering Co., Ltd The intact hepatitis c virus and the method for culturing it in a vitro cell culture
US7598362B2 (en) * 2001-10-11 2009-10-06 Merck & Co., Inc. Hepatitis C virus vaccine
US6689559B2 (en) * 2001-11-29 2004-02-10 The Research Foundation Of The State University Of New York Efficient hepatitis C virus replicon and its use in identifying antiviral compounds
ES2346717T3 (es) * 2002-03-11 2010-10-19 Lab 21 Limited Metodo y composiciones para identificar y caracterizar la hepatitis c.
KR100471946B1 (ko) * 2002-05-08 2005-03-08 (주)팬바이오넷 Ｃ형 간염바이러스(ｈｃｖ)의 리플리콘, 이를 포함하는세포주, 및 상기 세포주를 이용한 ｈｃｖ 탐지방법
WO2004005524A1 (en) * 2002-07-02 2004-01-15 Merck & Co., Inc. Hepatitis c virus particle formation
GB0222824D0 (en) * 2002-10-02 2002-11-06 Moredun Res Inst Bacteriophage-mediated immunisation II
US7115374B2 (en) * 2002-10-16 2006-10-03 Gen-Probe Incorporated Compositions and methods for detecting West Nile virus
US7927840B2 (en) * 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
EP1556082A1 (en) * 2002-10-22 2005-07-27 Aventis Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
US7455969B2 (en) * 2002-11-13 2008-11-25 Washington University Highly permissive cell lines for hepatitis C virus RNA replication
EP2423216B1 (en) 2003-12-01 2015-07-08 Board Of Regents, The University Of Texas System Replication competent hepatitis C virus and methods of use
CN1910275B (zh) * 2003-12-01 2011-04-27 威特克斯医药股份有限公司 包含胎儿肝细胞的组合物及其用于hcv感染的方法
US7364854B2 (en) * 2004-01-23 2008-04-29 Biomerieux, Inc Nucleotide mixture for improved nucleic acid amplification performance
CA2557790A1 (en) 2004-03-02 2005-09-15 Virco Bvba Estimation of clinical cut-offs
CA2558771C (en) * 2004-03-05 2013-01-08 Benitec, Inc. Multiple promoter expression cassettes for simultaneous delivery of rnai agents
US7833987B2 (en) * 2004-03-12 2010-11-16 Indian Institute Of Science Small synthetic RNA, a method of preparing the same and uses thereof
ATE488766T1 (de) * 2004-06-21 2010-12-15 Progenra Inc Diagnostik und screening-methode und kit in verbindung mit proteolytischer aktivität
US7785875B2 (en) 2004-07-03 2010-08-31 Mogam Biotechnology Research Institute Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
PL1797112T3 (pl) * 2004-09-29 2011-04-29 The Administrators Of The Tulane Educational Fund Inhibitory wirusa zapalenia wątroby typu C
JP2008530032A (ja) * 2005-02-16 2008-08-07 ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ 腫瘍治療のためのフラビウイルスレプリコン構築物
EP1863941B1 (en) * 2005-03-04 2013-05-08 The Rockefeller University Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
US20060234348A1 (en) * 2005-04-13 2006-10-19 Bujarski Jozef J Method of production of RNA polymerase protein
JP2007312649A (ja) * 2006-05-24 2007-12-06 Japan Health Science Foundation 再構築された感染性レトロウイルスゲノムクローンｄｎａ及びそれを含む微生物ならびにそれらの製造方法
AU2015234338C1 (en) * 2006-07-28 2017-07-20 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
US7504255B2 (en) * 2006-08-17 2009-03-17 Saint Louis University Compositions and methods for generation of infectious hepatitis C virus in immortalized human hepatocytes
US20080096274A1 (en) * 2006-10-24 2008-04-24 Guangpu Li Recombinant alphavirus vectors and methods of using same
AU2008338803B2 (en) * 2007-11-26 2015-02-05 Glaxosmithkline Biologicals S.A. Methods of generating alphavirus particles
US8921536B2 (en) 2008-10-29 2014-12-30 The Trustees Of The University Of Pennsylvania HCV vaccines and methods for using the same
WO2010050939A1 (en) * 2008-10-29 2010-05-06 The Trustees Of The University Of Pennsylvania Improved hcv vaccines and methods for using the same
US20100129902A1 (en) * 2008-11-24 2010-05-27 Erhard Ralf Schoenbrunner Replication Stable and RNase Resistant Chimeras of Pestivirus with Insertion in 3' Nontranslated Region (3'NTR)
JPWO2011024875A1 (ja) * 2009-08-28 2013-01-31 公益財団法人東京都医学総合研究所 Ｃ型肝炎ウイルスの新規株由来のポリヌクレオチド及びその利用
US20110070199A1 (en) * 2009-09-21 2011-03-24 Scheiber Ii Lane Bernard Adaptable modified virus vector to deliver ribosomal ribonucleic acid combined with messenger ribonucleic acid as a medical treatment device to manage diabetes mellitus and other protein deficient dieases
EP2705150B1 (en) * 2011-05-02 2020-07-29 The Johns Hopkins University A synthetic hepatitis c genome and methods of making and use
US20140242669A1 (en) * 2011-08-18 2014-08-28 Ycine Llc Production of infectious rna viruses in yeast
CA2962696A1 (en) 2014-10-01 2016-04-07 National Research Council Of Canada Animal models, cell lines and methods for screening hepatitis c virus vaccines

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5218099A (en) * 1986-04-01 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Post-transfusion, non-A, non-B hepatitis virus polynucleotides
ES2061500T5 (es) * 1986-06-17 2003-05-16 Chiron Corp Diagnosis y vacunas de la hepatitis delta, su preparacion y uso.
US5656731A (en) * 1987-10-15 1997-08-12 Chiron Corporation Nucleic acid-amplified immunoassay probes
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US5679342A (en) * 1987-11-18 1997-10-21 Chiron Corporation Hepatitis C virus infected cell systems
JPH02500880A (ja) * 1987-11-18 1990-03-29 カイロン　コーポレイション Ｎａｎｂｖの診断用薬およびワクチン
US5712088A (en) * 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US5714596A (en) * 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
GB2212511B (en) * 1987-11-18 1992-01-22 Chiron Corp Hepatitis c virus
US5698390A (en) * 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US5312737A (en) * 1988-03-11 1994-05-17 Abbott Laboratories CKS method of HCV protein synthesis
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5191064A (en) * 1988-09-30 1993-03-02 The Research Foundation For Microbial Diseases (Osaka University) Non-a, non-b hepatitis virus antigen peptide
JPH02167081A (ja) * 1988-12-21 1990-06-27 Tetsuo Nakamura 非Ａ非Ｂ型肝炎ウイルスゲノムＲＮＡ、ｃＤＮＡおよびウイルス抗原蛋白質
US5176994A (en) * 1988-12-21 1993-01-05 Immuno Japan Inc. Non-A, Non-B hepatitis virus genome RNA, cDNA and virus antigen protein
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
KR0185373B1 (ko) * 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
ATE161041T1 (de) * 1989-08-25 1997-12-15 Chiron Corp Verfahren zur hcv-züchtung in zell-linien aus b- oder t-lymphozyten
US5372928A (en) * 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
KR940000755B1 (ko) * 1990-02-16 1994-01-29 유나이티드 바이오메디칼 인코오포레이티드 Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드
US5106726A (en) * 1990-02-16 1992-04-21 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV
HU217025B (hu) * 1990-04-04 1999-11-29 Chiron Corp. Hepatitis C vírus-(HCV) antigénkészítmények az anti-HCV-antitestek kimutatására immunoassay-kben
DE69133402T2 (de) * 1990-04-04 2004-11-11 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Protease von hepatitis-c-virus
DE69132332T2 (de) * 1990-04-06 2000-11-30 Genelabs Technologies, Inc. Hepatitis c-virus-epitope
FI923020A0 (fi) * 1990-06-30 1992-06-29 Akzo Nv Inte a inte b-sekvenser.
KR0181517B1 (ko) * 1990-07-09 1999-04-01 나까하라 노부유끼 비-에이 비-비형 간염-특이 항원 및 간염 진단에서 그의 용도
SK286106B6 (sk) * 1990-11-08 2008-03-05 Novartis Vaccines & Diagnostics, Inc. Spôsob vykonávania imunodiagnostickej skúšky na detekciu protilátky proti vírusu hepatitídy C
US5654179A (en) * 1990-11-14 1997-08-05 Hri Research, Inc. Nucleic acid preparation methods
EP0510952A1 (en) * 1991-04-26 1992-10-28 Immuno Japan Inc. Oligonucleotide primers and their application for high-fidelity detection of non-a, non-b hepatitis virus
AT405053B (de) * 1991-06-10 1999-05-25 Lucky Ltd Hepatitis-c-diagnosemittel und -impfstoffe
ES2188583T3 (es) * 1991-06-24 2003-07-01 Chiron Corp Polipeptidos para el virus de la hepatitis c (hcv).
DK0613502T3 (da) * 1991-07-31 1999-06-28 Hoffmann La Roche Fremgangsmåde og reagenser til detektering af bakterier i cerebrospinalvæske
US5428145A (en) * 1991-08-09 1995-06-27 Immuno Japan, Inc. Non-A, non-B, hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems
ES2111589T3 (es) * 1991-08-27 1998-03-16 Hoffmann La Roche Metodos y reactivos para la deteccion de la hepatitis c.
EP0532258A2 (en) * 1991-09-09 1993-03-17 Immuno Japan Inc. Oligonucleotides and determination system of HCV genotypes
RU2212899C2 (ru) * 1991-09-13 2003-09-27 Чирон Корпорейшн Hcv иммунореактивные полипептидные композиции
US5576302A (en) * 1991-10-15 1996-11-19 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
JP3439209B2 (ja) * 1992-01-31 2003-08-25 アボツト・ラボラトリーズ Ｈｃｖ蛋白のための哺乳動物発現システム
JPH06105690A (ja) * 1992-03-10 1994-04-19 Kunitada Shimotoono 血液伝播性非ａ非ｂ型肝炎ウィルスｄｎａ
US5643578A (en) * 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5610054A (en) * 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5552310A (en) * 1992-06-12 1996-09-03 Hiroshi Yoshikura Replication of hepatitis C virus genome and identification of virus having high infectivity
JP2778886B2 (ja) * 1992-10-16 1998-07-23 エバーニュー バイオテック インコーポレイティド Ｃ型肝炎ウィルスのコア抗原タンパク質及びそれを用いての診断方法及びキット
JPH06153961A (ja) * 1992-11-27 1994-06-03 Imuno Japan:Kk Ｃ型肝炎ウイルス部分遺伝子、ならびにｃ型肝炎ウイルス遺 伝子の高感度検出法
AU6364094A (en) * 1993-03-12 1994-09-26 Board Of Regents, The University Of Texas System Anthracyclines with unusually high activity against cells resistant to doxorubicin and its analogs
TW275068B (https=) * 1993-09-24 1996-05-01 American Cyanamid Co
ATE475668T1 (de) * 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
US5861267A (en) * 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
US5874565A (en) * 1995-08-29 1999-02-23 Washington University Nucleic acids comprising a highly conserved novel 3 terminal sequence element of the hepatitis C virus
US5677124A (en) * 1996-07-03 1997-10-14 Ambion, Inc. Ribonuclease resistant viral RNA standards
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof

Also Published As

Publication number Publication date
US6392028B1 (en) 2002-05-21
EP1005366A1 (en) 2000-06-07
WO1998039031A1 (en) 1998-09-11
AU742175B2 (en) 2001-12-20
EP1005366A4 (en) 2004-05-19
CA2283464C (en) 2006-09-26
JP2001515353A (ja) 2001-09-18
US20020102540A1 (en) 2002-08-01
JP2008167755A (ja) 2008-07-24
ZA981838B (en) 1999-02-19
IL131688A (en) 2007-09-20
US6127116A (en) 2000-10-03
JP4223068B2 (ja) 2009-02-12
JP4094679B2 (ja) 2008-06-04
IL131688A0 (en) 2001-03-19
CA2283464A1 (en) 1998-09-11
AU6938698A (en) 1998-09-22
US20030073080A1 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
BR9808147A (pt) Clone de ácido nucleico do vìrus da hepatite c (hcv) geneticamente engenheirado, clone plasmìdeo que abriga uma cdna do hcv de tamanho natural, dna ou rna do hcv transcrito do cdna do hcv de comprimento natural, linhagem de célula hospedeira transfectada e in vitro infectada com o hcv, animal não humano infectado com o hcv, partìcula viral do hcv, sistema de teste in vitro, isento de célula para o hcv, vacina do hcv e conjunto de teste para o hcv e processos para identificar uma linhagem de célula que é permissiva e um animal que é permissivo para a infecção por hcv, para selecionar hcv com mutações adaptativas que permitem nìveis mais altos de replicação do hcv em uma linhagem de célula permissiva, para infectar uma animal com o hcv, para propagar o hcv in vitro, para transduzir um animal suscetìvel à infecção por hcv com um gene heterólogo, para produzir partìculas virais do hcv, proteìnas de partìcula do hcv e anticorpos do hcv, para separar agentes capazes de modular a replicação do hcv, para preparar um ácido nucleico do hcv e para detectar anticorpos do hcv em uma amostra biológica de um paciente.
Airenne et al. Baculovirus-mediated periadventitial gene transfer to rabbit carotid artery
Bowen et al. Adenovirus vector-induced inflammation: capsid-dependent induction of the CC chemokine RANTES requires NF-κ B
Löser et al. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFκB
Borgland et al. Adenovirus vector-induced expression of the CXC chemokine IP-10 is mediated through capsid-dependent activation of NF-κB
Strayer et al. Use of SV40-based vectors to transduce foreign genes to normal human peripheral blood mononuclear cells
Usherwood et al. Latent antigen vaccination in a model gammaherpesvirus infection
Banerjee et al. Therapeutic gene delivery in human B-lymphoblastoid cells by engineered non-transforming infectious Epstein–Barr virus
US20080166373A1 (en) METHODS AND COMPOSITIONS FOR DELIVERY AND EXPRESSION OF INTERFERON-alpha NUCLEIC ACIDS
EP0851769A1 (en) Gene therapy using ovine adenoviral vectors
JP2004536572A (ja) 新規ベクター構築物
Soukupová et al. Improvement of HSV-1 based amplicon vectors for a safe and long-lasting gene therapy in non-replicating cells
Macrae et al. Murid herpesvirus 4 strain 68 M2 protein is a B-cell-associated antigen important for latency but not lymphocytosis
Rund et al. Efficient transduction of human hematopoietic cells with the human multidrug resistance gene 1 via SV40 pseudovirions
Lu et al. Woodchuck gamma interferon upregulates major histocompatibility complex class I transcription but is unable to deplete woodchuck hepatitis virus replication intermediates and RNAs in persistently infected woodchuck primary hepatocytes
Detjen et al. Poliovirus single-stranded RNA and double-stranded RNA: differential infectivity in enucleate cells
WO2000022137A3 (en) Selectively replicating viral vectors
Lancaster et al. Persistence of viral DNA in human cell cultures infected with human papilloma virus
Thomas et al. Gene transfer into rat brain using adenoviral vectors
EP0962525A1 (en) Phage bonded to nuclear location signal
US20070059833A1 (en) Use of Nucleases to Improve Viability and Enhance Transgene Expression in Transfected Cells
CN108103094B (zh) 用于靶向抑制hiv-1前病毒表达的表达载体及其制备方法和应用
Oualikene et al. Lack of evidence of phenotypic complementation of E1A/E1B-deleted adenovirus type 5 upon superinfection by wild-type virus in the cotton rat
Wilkinson Gene therapy and viral vaccination
Samantaray et al. Human Adenovirus Serotypes Efficiently Transducing HEK293 Cells: An In Vitro Propagation of HAdv

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR.